We use cookies for various purposes including enabling website functionality and targeted marketing activities. For more information about cookies, please review our Privacy & Cookie Notice.
Accreditation information
Target Audience
This activity is intended for oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists engaged in the care of patients with lung cancer.
Learning Objectives
- Integrate molecular profiling results, tumor characteristics, and individual patient factors into evidence-based treatment decisions for patients with lung cancer
- Appraise emerging clinical trial safety and efficacy data in order to guide individualized clinical decision-making in lung cancer care
- Evaluate and implement appropriate interventions to reduce and manage treatment-related adverse events that may occur during the course of lung cancer care
- Develop strategies to address barriers and enhance enrollment of both healthcare professionals and patients with lung cancer in clinical trials
Accreditation
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Bio Ascend. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive CME credit points, you MUST pass the posttest and complete the evaluation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty disclosure information coming soon.
Instructions for Credit
To receive CE credit, learners must follow these steps:
- Link for activity evaluation coming soon
- Complete the activity evaluation
- Upon completion of all evaluation questions, your credit will be made available for download immediately.
ALCS 2025 COI Faculty
Fatemeh Ardeshir, MD, MSc
Has no relevant financial relationships
Ioana Bonta, MD
Consultant, Advisor, Speaker: AstraZeneca, Daiichi Sanyko, Genentech, Jensen Scientific, Johnson and Johnson, Regeneron, Roche
Hossein Borghaei, DO, MS
Consultant, Advisor, Speaker:
AbbVie, Amgen, AstraZeneca,
Astellas, Axiom, Bayer, Beigene,
BerGenBio, BioNTech, Boehringer
Ingelheim, BMS, Daiichi Sankyo,
EMD-Serono, Genentech, Genmab,
Gilead, Grid Therapeutics, Guardant,
iTEO, Iobiotech, Janssen, Jazz
Pharmaceuticals, Lilly, Merck, Mirati,
Natera, Novartis, Novocure,
Oncocyte, Pfizer, Puma, RAPT,
Regeneron, Summit, Systimmune,
Takeda
Researcher: Amgen, BMS, Lilly
DSMB Member/Chair: Incyte, UPenn:
CAR-T Program, Novartis, Servier,
Springworks, Takeda
Paul Bunn, MD
Consultant, Advisor, Speaker: AstraZeneca, Aveo, BMS, Daiichi Sankyo, Dizal, Genentech, Merck, Verastem
Jennifer Carlisle, MD
Consultant, Advisor, Speaker: Amgen, AstraZeneca, Catalyst, Lilly
Jamie Chaft, MD
Consultant, Advisor, Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Guardant, Exact Sciences, FMI, Merck, Natera
Researcher: AstraZeneca, Boehringer Ingelheim, Genentech, Lilly,
Merck, BioNtech, Taiho
Trevor Feinstein, MD
Consultant, Advisor, Speaker: AstraZeneca, BeyondSpring, Johnson and Johnson, Recodati, Sanofi, Sobi
Shirish Gadgeel, MD
Consultant, Advisor, Speaker: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Genentech, Gilead, Johnson and Johnson, Pfizer, Takeda
Paul Gill, MD
Has no relevant financial relationships
John Heymach, MD, PhD
Has no relevant financial relationships
Mohan Krishnamachary, MD
Has no relevant financial relationships
Onkar Khullar, MD, MSc
Has no relevant financial relationships
Ticiana Leal, MD
Consultant, Advisor, Speaker: AbbVie, Amgen, AstraZeneca, Black Diamond Therapeutics, BMS, Boehringer Ingelheim, Catalyst, Genentech, Gilead, Jazz, Johnson and Johnson, Novartis, Novocure, OncoC4, Pfizer, Regeneron, Roche, Sanofi, Synthekine, Takeda
Steve McCune, MD, PhD
Consultant, Advisor, Speaker: BMS
Kelsey Pan, MD, MPH
Consultant, Advisor, Speaker: Janssen Pharmaceuticals
Suresh Ramalingam, MD, FACP, FASCO
Grant or Research Support to institution: Amgen, AstraZeneca, BMS, Gilead, Johnson and Johnson, Merck, Pfizer
Gregory Riely, MD, PhD
Researcher: Amgen, Lilly, Mirati/BMS, Takeda
Joshua Sabari, MD
Consultant, Advisor, Speaker: AstraZeneca, AbbVie, Boehringer Ingelheim, Genentech, J&J Janssen, Jazz, Loxo, Lilly, BMS/Mirati, Pfizer, Regeneron, Revolution Medicines, Sanofi Genzyme, Takeda
Conor Steuer, MD
Consultant, Advisor, Speaker: BMS, Boehringer Ingelheim, Daiichi Sankyo, Fennec, Merck, Novocure, Regeneron
Sibo Tian, MD
Consultant, Advisor, Speaker: Castle, Merck
Researcher: Varian
Heather Wakelee, MD
Consultant, Advisor, Speaker: AstraZeneca, Beigene(BeOne), BMS, GSK, Genentech/Roche, IOBioTech, Mirati, OncoC4
Researcher: AstraZeneca, Bayer, BMS,
Genentech/Roche, Helsinn, Merck,
SeaGen, Xcovery, Gilead via IIT
(Georgetown)